Drugs / BETAHISTINE MESILATE
BETAHISTINE MESILATE
also known as
Merislon · Betahistine dimesylate · Betahistine dimethanesulfonate · Betahistine Mesilate Tablets
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT00474409 | May 2007 → ? | peripheral vertigo | Eisai Inc. | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase not applicable1 trial | ||||||
| — | NCT05604937 | Feb → Jun 2023 | Barre-Lieou syndrome | Zhan Yunfan | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-03-29 | Eisai Inc. | EISAI TO DIVEST RIGHTS FOR MERISLON® AND MYONAL® IN JAPAN TO KAKEN PHARMACEUTICAL eisai.com ↗ |
| 2022-11-07 | Eisai Inc. | EISAI TO DIVEST RIGHTS FOR MUSCLE RELAXANT MYONAL® AND VERTIGO AND EQUILIBRIUM DISTURBANCE TREATMENT MERISLON® IN ASIA TO DKSH eisai.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BETAHISTINE MESILATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298035 ↗ |
| Known as | Betahistine dimesylate | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298035 ↗ |
| Known as | Betahistine dimethanesulfonate | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298035 ↗ |
| Known as | Betahistine Mesilate Tablets | “Merislon (Betahistine Mesilate Tablets), specification 6mg, Sinopharm H20040130, Eisai (China) Pharmaceutical Co., LTD., is given to patients of the control group, for 2 weeks,...” NCT05604937 ↗ |
| Known as | Merislon | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00474409 ↗ |